Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 6/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 6/20 | 0.42 |
| ▸ | PPARG | P37231 | 4/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | F2RL3 | Q96RI0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488346 | 0.93 | PPARG (0.45) | PPARGALOX5AP | |
| SCHEMBL6500991 | 0.90 | ALOX5AP (0.42) | PPARGALOX5APMAPTSMN1; SMN2 | |
| SCHEMBL6488564 | 0.88 | AGTR1 (0.44) | MEN1CYP3A4CYP2C9CYP2C19HTT | |
| SCHEMBL6491428 | 0.82 | BCL2 (0.46) | PPARGALOX5APMAPT | |
| SCHEMBL6488968 | 0.80 | PPARG (0.50) | PPARGALOX5APLMNAMAPTSMN1; SMN2 | |
| SCHEMBL6500822 | 0.80 | AGTR1 (0.47) | — | |
| SCHEMBL6498787 | 0.79 | BCL2 (0.40) | PPARGALOX5APMAPT | |
| SCHEMBL6488562 | 0.79 | AGTR1 (0.41) | — | |
| SCHEMBL6488086 | 0.78 | ALOX5AP (0.42) | PPARGALOX5APLMNAMAPTSMN1; SMN2 | |
| SCHEMBL6488074 | 0.77 | AGTR1 (0.43) | ALOX5APMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014812-A1 | Benzimidazole compounds | SLC5A1, SLC5A2, G6PD | MTNR1A 2935/4885MTNR1B 1875/4885PPARG 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.